[Graft-versus-host disease-free, and relapse-free survival in Japanese patients with hematological malignancies].
Graft-versus-host disease (GVHD) -free, relapse-free survival (GRFS) is an important, composite endpoint for clinical trials, which provides a patient-centered measure of transplant success. This review discusses the results of the Japanese Transplant Registry study. This large-scale study examined 23,302 patients with hematological malignancy and characterized GRFS according to a variety of graft sources. The GRFS rate at 1 year was 41% in all patients. GRFS was superior in patients undergoing bone marrow transplantation compared to peripheral blood stem cell transplantation, owing to lower risk of developing grades III-IV acute and chronic GVHD. The best GRFS rates were observed in patients that received HLA-matched related bone marrow transplants; however, this was not the case in HLA-mismatched donors. GRFS after single-cord blood transplantation was almost comparable with HLA-matched unrelated bone marrow transplantation, possibly due to the low risk of chronic GVHD. Other factors associated with increased GRFS rates included female patients; use of anti-thymocyte globulin prophylaxis for standard-risk disease; recent transplantations; gender combinations other than from a female donor to a male patient; absence of prior autologous transplantation; myeloablative conditioning; negative cytomegalovirus serostatus; and use of tacrolimus-based GVHD prophylaxis. These results provide valuable information for deciding the best choice of graft sources and type of GVHD prophylaxis to be used.